Abstract:Inherited blood disorders comprise a large spectrum of diseases due to germline mutations in genes with key function in the hematopoietic system; they include immunodeficiencies, anemia or metabolic diseases. For most of them the only curative treatment is bone marrow transplantation, a procedure associated to severe complications; other therapies include red blood cell and platelet transfusions, which are dependent on donor availability. An alternative option is gene therapy, in which the wild-type form of the mutated gene is delivered into autologous hematopoietic stem cells using viral vectors. A more recent therapeutic perspective is gene correction through CRISPR/Cas9-mediated gene editing, that overcomes safety concerns due to insertional mutagenesis and allows correction of base substitutions in large size genes difficult to incorporate into vectors. However, applying this technique to genomic disorders caused by large gene deletions is challenging. Chromosomal transplantation has been proposed as a solution, using a universal source of wild-type chromosomes as donor, and induced pluripotent stem cells (iPSCs) as acceptor. One of the obstacles to be addressed for translating PSC research into clinical practice is the still unsatisfactory differentiation into transplantable hematopoietic stem or mature cells. We provide an overview of the recent progresses in this field and discuss challenges and potential of iPSC-based therapies for the treatment of inherited blood disorders.

Hematopoietic Stem Cell Gene Therapy: Progress and Lessons Learned

Advancements in Hematopoietic Stem Cell Gene Therapy: A Journey of Progress for Viral Transduction

Hematopoietic stem and progenitors cells gene editing: Beyond blood disorders

[Development of hematopoietic stem cell-targeted gene therapy]

Therapy Development by Genome Editing of Hematopoietic Stem Cells

Gene Editing of Hematopoietic Stem Cells: Hopes and Hurdles Toward Clinical Translation

Gene therapy using haematopoietic stem and progenitor cells

Successes and challenges in clinical gene therapy

International Society for Cell & Gene Therapy Stem Cell Engineering Committee report on the current state of hematopoietic stem and progenitor cell-based genomic therapies and the challenges faced

Advances and Obstacles in Homology-Mediated Gene Editing of Hematopoietic Stem Cells

Hematopoietic Cells from Pluripotent Stem Cells: Hope and Promise for the Treatment of Inherited Blood Disorders

Hematopoietic Stem Cell Gene-Addition/Editing Therapy in Sickle Cell Disease

Progress in the field of hematopoietic stem cell-based therapies for inborn errors of immunity

Hematopoietic stem cell collection for sickle cell disease gene therapy

Genome Editing Therapy for the Blood: Ex Vivo Success and In Vivo Prospects

Cell and Gene Therapy for Anemia: Hematopoietic Stem Cells and Gene Editing

In Vivo Hematopoietic Stem Cell Transduction

Gene Therapies for Hemoglobinopathies: Promises and Challenges

In Vivo Selection for Gene-Corrected HSPCs Advances Gene Therapy for a Rare Stem Cell Disease

Current approaches and potential challenges in the delivery of gene editing cargos into hematopoietic stem and progenitor cells

Hematopoietic Stem Cell Transplantation in Sickle Cell Disease: A Multidimentional Review